Endogenous neurosteroids and their synthetic analogs (neuroactive steroids) are potent modulators of GABA A receptors. Thus, they are of physiological and clinical relevance for their ability to modulate inhibitory function in the CNS. Despite their importance, fundamental issues of neurosteroid actions remain unresolved. Recent evidence suggests that glutamatergic principal neurons, rather than glia, are the major sources of neurosteroid synthesis. Other recent studies have identified putative neurosteroid binding sites on GABA A receptors. In this Opinion, we argue that neurosteroids require a membranous route of access to transmembrane-domain binding sites within GABA A receptors. This has implications for the design of future neuroactive steroids because the lipid solubility and related accessibility properties of the ligand are likely to be key determinants of receptor modulation.
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Overview
Endogenous neurosteroids and their synthetic analogs (neuroactive steroids) are among the most potent and effective modulators of g-aminobutyric acid-A (GABA A ) receptors known [1] . Although a role for neurosteroids as endogenous modulators has been postulated for nearly thirty years, fundamental issues of neurosteroid actions on circuits, cells, and receptors remain unresolved. For instance, which cells in the CNS synthesize neurosteroids? Once synthesized, how, where, and at what concentrations do these modulators reach their target receptors? Recent evidence suggests that principal neurons, rather than glia, could dominate CNS neurosteroid synthesis. Other studies have identified putative neurosteroid binding sites on GABA A receptors. Parallel pharmacological approaches have implied a non-classical interaction between neurosteroid ligands and GABA A receptors, involving a membrane route of access and a low-affinity receptor interaction for neurosteroids. Here, we discuss our opinion that local synthesis and a non-classical transmembrane binding site for neurosteroids suggest very local actions for neurosteroids that differ from the diffuse, hormonal effects usually associated with steroid actions. We also argue that the atypical nature of the neurosteroid interaction with GABA A receptors implies that future drug design should consider both specific (drug pharmacophore) and nonspecific (membranous access) properties of the ligand.
Neurosteroid synthesis and CNS effects
Neurosteroids augment GABAergic inhibition by two principal effects. At low nanomolar aqueous concentrations they potentiate the actions of GABA, increasing receptor sensitivity and GABA's effectiveness, through specific changes in the kinetics of GABA-activated channels [1] [2] [3] . At higher concentrations, neurosteroids directly open GABA A channels in the absence of GABA. Although both actions enhance inhibition, potentiation probably dominates both endogenous modulation and exogenous drug actions. Neurosteroid effects do not strictly depend on specific GABA A receptor subunits, but effects are greater at certain receptor subtypes and depend on GABA concentration, the receptor's affinity for GABA, and the efficacy with which GABA gates its channel. The threshold for potentiation by (3a,5a)-3-hydroxypregnan-20-one (allopregnanolone or 3a5aP) is 1-10 nM, with maximal enhancement of up to 20-fold at low GABA concentration. Interestingly, enhancement by low neurosteroid concentrations develops more slowly during exogenous administration than expected from simple aqueous diffusion to a receptor site [3] [4] [5] .
At synapses, where GABA achieves brief, high concentrations, neurosteroids enhance postsynaptic charge transfer by prolonging the decay of inhibitory postsynaptic currents (IPSCs) [6] . Neurosteroids also augment tonic inhibition at extrasynaptic GABA A receptors [7] , particularly those containing delta (d) subunits. GABA gates dcontaining channels with low efficacy, and neurosteroids potentiate partly by increasing GABA efficacy [8, 9] . The large effects on d-containing receptors have led to the proposal that they could be preferred sites of action of neurosteroids.
Neurosteroids also target non-GABA A receptors and channels [10] [11] [12] [13] [14] . For example, sulfated neurosteroids affect N-methyl-D-aspartate (NMDA) receptors at supraphysiological concentrations and s1 receptors at low, physiological concentrations. Modulation of these receptors, like modulation of GABA A receptors, influences behavior and could be important for the etiology and treatment of 
